S&P 500   3,975.32 (+0.97%)
DOW   32,240.89 (+0.66%)
QQQ   311.06 (+1.61%)
AAPL   159.94 (+1.34%)
MSFT   279.46 (+2.63%)
META   205.92 (+3.06%)
GOOGL   105.95 (+2.50%)
AMZN   99.91 (+1.23%)
TSLA   193.34 (+1.15%)
NVDA   272.42 (+2.92%)
NIO   9.32 (+2.53%)
BABA   86.22 (+3.07%)
AMD   101.25 (+3.76%)
T   18.51 (+0.65%)
F   11.60 (+1.05%)
MU   61.39 (+5.54%)
CGC   1.91 (+1.33%)
GE   91.66 (+2.31%)
DIS   96.54 (+1.73%)
AMC   4.46 (+2.76%)
PFE   40.36 (+0.87%)
PYPL   73.25 (-1.47%)
NFLX   318.65 (+8.42%)
S&P 500   3,975.32 (+0.97%)
DOW   32,240.89 (+0.66%)
QQQ   311.06 (+1.61%)
AAPL   159.94 (+1.34%)
MSFT   279.46 (+2.63%)
META   205.92 (+3.06%)
GOOGL   105.95 (+2.50%)
AMZN   99.91 (+1.23%)
TSLA   193.34 (+1.15%)
NVDA   272.42 (+2.92%)
NIO   9.32 (+2.53%)
BABA   86.22 (+3.07%)
AMD   101.25 (+3.76%)
T   18.51 (+0.65%)
F   11.60 (+1.05%)
MU   61.39 (+5.54%)
CGC   1.91 (+1.33%)
GE   91.66 (+2.31%)
DIS   96.54 (+1.73%)
AMC   4.46 (+2.76%)
PFE   40.36 (+0.87%)
PYPL   73.25 (-1.47%)
NFLX   318.65 (+8.42%)
S&P 500   3,975.32 (+0.97%)
DOW   32,240.89 (+0.66%)
QQQ   311.06 (+1.61%)
AAPL   159.94 (+1.34%)
MSFT   279.46 (+2.63%)
META   205.92 (+3.06%)
GOOGL   105.95 (+2.50%)
AMZN   99.91 (+1.23%)
TSLA   193.34 (+1.15%)
NVDA   272.42 (+2.92%)
NIO   9.32 (+2.53%)
BABA   86.22 (+3.07%)
AMD   101.25 (+3.76%)
T   18.51 (+0.65%)
F   11.60 (+1.05%)
MU   61.39 (+5.54%)
CGC   1.91 (+1.33%)
GE   91.66 (+2.31%)
DIS   96.54 (+1.73%)
AMC   4.46 (+2.76%)
PFE   40.36 (+0.87%)
PYPL   73.25 (-1.47%)
NFLX   318.65 (+8.42%)
S&P 500   3,975.32 (+0.97%)
DOW   32,240.89 (+0.66%)
QQQ   311.06 (+1.61%)
AAPL   159.94 (+1.34%)
MSFT   279.46 (+2.63%)
META   205.92 (+3.06%)
GOOGL   105.95 (+2.50%)
AMZN   99.91 (+1.23%)
TSLA   193.34 (+1.15%)
NVDA   272.42 (+2.92%)
NIO   9.32 (+2.53%)
BABA   86.22 (+3.07%)
AMD   101.25 (+3.76%)
T   18.51 (+0.65%)
F   11.60 (+1.05%)
MU   61.39 (+5.54%)
CGC   1.91 (+1.33%)
GE   91.66 (+2.31%)
DIS   96.54 (+1.73%)
AMC   4.46 (+2.76%)
PFE   40.36 (+0.87%)
PYPL   73.25 (-1.47%)
NFLX   318.65 (+8.42%)
NASDAQ:IMTX

Immatics - IMTX Competitors

$6.78
-0.22 (-3.14%)
(As of 03/23/2023 01:33 PM ET)
Add
Compare
Today's Range
$6.76
$7.09
50-Day Range
$7.00
$8.88
52-Week Range
$5.75
$13.60
Volume
235,963 shs
Average Volume
207,770 shs
Market Capitalization
$516.84 million
P/E Ratio
10.12
Dividend Yield
N/A
Price Target
$27.00

IMTX vs. AGEN, NVAX, JATT, HLVX, FDMT, FATE, EDIT, ALEC, CHRS, and SRRK

Should you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Agenus (AGEN), Novavax (NVAX), JATT Acquisition (JATT), HilleVax (HLVX), 4D Molecular Therapeutics (FDMT), Fate Therapeutics (FATE), Editas Medicine (EDIT), Alector (ALEC), Coherus BioSciences (CHRS), and Scholar Rock (SRRK). These companies are all part of the "biological products, except diagnostic" industry.

Immatics vs.

Immatics (NASDAQ:IMTX) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.

Immatics has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immatics$41.13 million12.97-$110.43 million$0.6710.45
Agenus$98.02 million5.16-$220.07 million-$0.79-1.92

Immatics has a net margin of 24.60% compared to Agenus' net margin of -235.30%. Immatics' return on equity of 40.49% beat Agenus' return on equity.

Company Net Margins Return on Equity Return on Assets
Immatics 24.60% 40.49% 12.91%
Agenus -235.30% -1,159.04% -53.02%

Agenus received 435 more outperform votes than Immatics when rated by MarketBeat users. However, 70.97% of users gave Immatics an outperform vote while only 70.52% of users gave Agenus an outperform vote.

CompanyUnderperformOutperform
ImmaticsOutperform Votes
22
70.97%
Underperform Votes
9
29.03%
AgenusOutperform Votes
457
70.52%
Underperform Votes
191
29.48%

29.1% of Immatics shares are owned by institutional investors. Comparatively, 53.8% of Agenus shares are owned by institutional investors. 4.8% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Agenus had 18 more articles in the media than Immatics. MarketBeat recorded 25 mentions for Agenus and 7 mentions for Immatics. Immatics' average media sentiment score of 0.30 beat Agenus' score of 0.24 indicating that Immatics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immatics
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Agenus
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immatics presently has a consensus target price of $27.00, suggesting a potential upside of 285.71%. Agenus has a consensus target price of $7.10, suggesting a potential upside of 367.11%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Immatics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immatics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Agenus
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Immatics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

Summary

Immatics beats Agenus on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMTX vs. The Competition

MetricImmaticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$533.61M$2.58B$4.30B$5.81B
Dividend YieldN/A2.30%2.40%4.47%
P/E Ratio10.455.48154.3615.47
Price / Sales12.97165.893,526.9957.69
Price / CashN/A15.0319.7657.16
Price / Book15.562.614.455.01
Net Income-$110.43M$67.29M$115.42M$190.83M
7 Day Performance-9.56%-2.80%-2.46%-1.39%
1 Month Performance-20.45%2.85%-6.55%-6.86%
1 Year Performance-7.04%-24.96%-16.11%-18.39%

Immatics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGEN
Agenus
2.1109 of 5 stars
$1.52
-6.7%
$7.10
+367.1%
-45.5%$542.00M$98.02M-1.92441
NVAX
Novavax
2.0273 of 5 stars
$5.78
-4.0%
$70.67
+1,122.6%
-93.1%$518.76M$1.98B-0.691,992Analyst Revision
JATT
JATT Acquisition
0 of 5 stars
$30.00
+314.4%
N/A-26.8%$517.50MN/A0.002,021High Trading Volume
HLVX
HilleVax
2.0224 of 5 stars
$15.32
-1.4%
$32.00
+108.9%
N/A$510.92MN/A-1.1715Analyst Revision
News Coverage
FDMT
4D Molecular Therapeutics
2.0977 of 5 stars
$16.85
-4.7%
$37.14
+120.4%
+2.7%$559.93M$3.13M-5.08124Analyst Revision
News Coverage
FATE
Fate Therapeutics
2.3599 of 5 stars
$5.15
-5.0%
$24.69
+379.4%
-86.4%$505.52M$96.30M-1.77449Analyst Upgrade
EDIT
Editas Medicine
2.3482 of 5 stars
$7.30
-9.3%
$15.33
+110.0%
-60.5%$503.48M$19.71M-2.27264
ALEC
Alector
2.4797 of 5 stars
$5.85
-4.9%
$15.38
+162.8%
-61.5%$485.73M$133.62M-3.63208High Trading Volume
CHRS
Coherus BioSciences
1.9157 of 5 stars
$5.89
-3.4%
$15.83
+168.8%
-52.6%$485.62M$211.04M-1.57332
SRRK
Scholar Rock
1.9062 of 5 stars
$9.15
-2.5%
$25.67
+180.5%
-29.6%$475.71M$33.19M-4.01145
This page (NASDAQ:IMTX) was last updated on 3/23/2023 by MarketBeat.com Staff